Presentations – Salvador HIV Clinical Forum, Brazil

 

Thursday 29 August 2019

 Session 1: Integrase Inhibitor Characteristics
 Boucher, Charles 2017Resistance to INSTIs and how resistance impacts treatment choices

Charles Boucher, MD, PhD - Erasmus Medical Center, The Netherlands

 Pharmacology considerations when choosing INSTIs
David Back, PhD - University of Liverpool, United Kingdom
 Toxicity considerations when choosing INSTIs
Ian Frank, MD - University of Pennsylvania, United States
 Session 2: Optimal Use of INSTIs in the Clinic
 Schechter, Mauro 2018Role of INSTIs in HIV prevention
Mauro Schechter, MD, PhD - Federal University of Rio de Janeiro, Brazil
 ​Experience with Dolutegravir in first line in Brazil
Ricardo Diaz, MD - Federal University of Sao Paulo, Brazil
 Switching to INSTs based treatment in viral suppressed patients
Ian Frank, MD - University of Pennsylvania, United States
 Clinical Case
Fabianna Bahia, MD, PhD - Universitary Hospital Professor Edgard Santos, Brazil
 Session 3: INSTI use in special populations
 INSTIs use in women at child-bearing age - NTD risks
Isabella Nóbrega, MD - Centro Especializado Em Diagnostico, Assistencia E Pesquisa, Brazil
 INSTIs use in pediatrics
Jorge Pinto, MD - Universidade Federal de Minas Gerais, Brazil
 Treatment options for HIV-TB coinfection
Carlos Brites, MD - Universidade Federal da Bahia, Brazil
 Session 4: HIV Therapy in the near future
 Time to change the paradigm - 2 vs 3 drugs
Estevão Nunes, MD - Fundação Oswaldo Cruz, Brazil
 Long Acting ARV - Drugs & Delivery systems
David Back, PhD - University of Liverpool, United Kingdom